类风湿关节炎风险中基因-呼吸系统疾病交互作用的新发现
该病例对照研究利用Mayo Clinic和Mass General Brigham生物样本库,在1,125例 incident RA和4,495例对照中识别与RA风险相关的基因-呼吸系统交互作用。发现间质性肺病和总体呼吸负担与RA相关,并验证了CD83/RNF182-急性咽炎(血清阴性RA)和JARID2-哮喘(血清阳性RA)等交互作用。
要点
- 间质性肺病与总体呼吸负担与incident RA风险相关。
- CD83/RNF182-急性咽炎交互作用在血清阴性RA中验证,呈剂量反应。
- JARID2-哮喘交互作用在血清阳性RA中验证。
核心结论
- 研究识别了新的呼吸系统风险因素和基因-呼吸系统内型,可能有助于RA的预防、诊断和治疗。
研究设计与样本
- 病例对照研究,使用Mayo Clinic(MC)和Mass General Brigham(MGB)生物样本库分别进行发现和验证。
- criteria-confirmed incident RA病例按年龄、性别和EHR历史时长与4例非RA对照匹配。
- 遗传暴露包括已知RA风险等位基因,呼吸疾病通过代码识别,呼吸负担定义为索引日期前呼吸代码总数除以EHR时长。
- 使用 logistic 回归模型调整潜在混杂因素,估计基因与呼吸暴露交互作用的OR及95%CI。
主要发现
- MC中识别1,125例incident RA病例和4,495例非RA对照(平均年龄64岁,70%女性;MGB中54岁,76%女性)。
- MC中间质性肺病(OR 1.55,95%CI 1.00-2.40)和总体呼吸负担(OR 1.67,95%CI 1.30-2.15)与incident RA相关。
- MGB中验证四个新基因-呼吸交互作用,包括CD83/RNF182(rs12530098)-急性咽炎与血清阴性RA(MC OR 4.06 [95%CI 1.61-10.3];MGB OR 3.68 [95%CI 1.42-9.56])。
- JARID2(rs113532504)-哮喘与血清阳性RA(MC OR 2.66 [95%CI 1.30-5.44];MGB OR 1.93 [95%CI 1.20-3.08])。
- CD83/RNF182-急性咽炎交互作用显示最强剂量反应关联(最高呼吸负担OR 8.54 [95%CI 1.59-45.9])。
关键数值与推荐
- 间质性肺病OR 1.55(95%CI 1.00-2.40)与incident RA相关。
- 总体呼吸负担OR 1.67(95%CI 1.30-2.15)与incident RA相关。
- CD83/RNF182-急性咽炎与血清阴性RA:MC OR 4.06(95%CI 1.61-10.3),MGB OR 3.68(95%CI 1.42-9.56)。
- JARID2-哮喘与血清阳性RA:MC OR 2.66(95%CI 1.30-5.44),MGB OR 1.93(95%CI 1.20-3.08)。
- CD83/RNF182-急性咽炎最高呼吸负担OR 8.54(95%CI 1.59-45.9)。
临床怎么用
- 呼吸系统疾病史(如间质性肺病、急性咽炎、哮喘)可能用于RA风险分层。
- 基因-呼吸交互作用内型可能指导RA的预防和早期诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to identify the strongest individual gene-respiratory interactions for rheumatoid arthritis (RA) risk. METHODS: This case-control study used the Mayo Clinic (MC) and Mass General Brigham (MGB) biobanks for discovery and validation, respectively. We matched criteria-confirmed incident RA cases to four non-RA controls on age, sex, and duration electronic health record (EHR) history. Genetic exposures included known RA risk alleles. We identified respiratory diseases by codes and defined "respiratory burden" as the total number of respiratory codes divided by EHR duration before index date of RA. Using logistic regression models adjusting for potential confounders, we estimated odds ratios (OR) with 95% confidence intervals (CI) for the interactions between genetic and respiratory exposures for RA risk. RESULTS: We identified 1,125 incident RA cases and 4,495 non-RA controls (mean age 64 years, 70% female in MC; 54 years, 76% female in MGB). In MC, both interstitial lung disease (OR 1.55, 95% CI 1.00-2.40) and overall respiratory burden (OR 1.67, 95% CI 1.30-2.15) were associated with incident RA. Four novel gene-respiratory interactions validated in MGB including CD83/RNF182 (rs12530098)-acute pharyngitis for seronegative RA (OR 4.06 [95% CI 1.61-10.3] MC; 3.68 [95% CI 1.42-9.56] MGB) and JARID2 (rs113532504)-asthma for seropositive RA (OR 2.66 [95% CI 1.30-5.44] MC; 1.93 [95% CI 1.20-3.08] MGB). The CD83/RNF182-acute pharyngitis interaction exhibited the strongest dose-response association (OR 8.54 [95% CI 1.59-45.9] for highest respiratory burden). CONCLUSION: This study identified novel respiratory risk factors and gene-respiratory endotypes for RA, which may be useful for RA prevention, diagnosis, and treatment.
引用
- Kronzer VL, Brooks RT, Shurtz AK, et al. Identifying the strongest novel gene-respiratory disease interactions for rheumatoid arthritis risk. Semin Arthritis Rheum. 2026. PMID: 41713227. doi:10.1016/j.semarthrit.2026.152937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。